(Hyperprolactinemia) articles in PubMed
- ''PCOS remains a diagnosis of exclusion: a concise review of key endocrinopathies to exclude''. [Journal Article]
- Clin Endocrinol (Oxf) 2016 Sep 24CE
- Polycystic ovarian syndrome (PCOS) is a heterogenous disorder associated with clinical, endocrine and ultrasonographic features that can also be encountered in a number of other diseases. It has trad...
Polycystic ovarian syndrome (PCOS) is a heterogenous disorder associated with clinical, endocrine and ultrasonographic features that can also be encountered in a number of other diseases. It has traditionally been suggested that prolactin excess, enzymatic steroidogenic abnormalities and thyroid disorders need to be excluded before a diagnosis of PCOS is made. However, there is paucity of data regarding the prevalence of PCOS-phenotype in some of these disorders, whereas other endocrine diseases that exhibit PCOS-like features may elude diagnosis and proper management if not considered. The present article reviews the data of currently included entities that exhibit a PCOS-phenotype and those that potentially need to be looked for, and attempts to identify specific features that distinguish them from idiopathic PCOS. This article is protected by copyright. All rights reserved.
- The Effect of Antipsychotics on Bone Mineral Density and Sex Hormones in Male Patients with Schizophrenia. [Journal Article]
- Psychiatr Danub 2016; 28(3):255-262PD
- CONCLUSIONS: The long-term use of prolactin - raising antipsychotic medications as well as hyperprolactinemia and hypoestrogenism accelerate bone degradation.
- Antipsychotic treatment, prolactin, and breast tumorigenesis. [Journal Article]
- Psychiatr Danub 2016; 28(3):243-254PD
- CONCLUSIONS: The role of PRL in breast carcinogenesis therefore remains unclear, unconfirmed, yet controversial. Antipsychotics should not be withhold for breast cancer prevention reasons to patients in need of this sometimes life-saving medication, even if classical breast cancer risk factors are present.
- Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study. [Journal Article]
- Pharmacopsychiatry 2016 Sep 22P
- Introduction: Although adjunctive aripiprazole improves hyperprolactinemia, sufficient evidence for its effects on sexual dysfunction has not been obtained. We assessed the usefulness of adjunctive a...
Introduction: Although adjunctive aripiprazole improves hyperprolactinemia, sufficient evidence for its effects on sexual dysfunction has not been obtained. We assessed the usefulness of adjunctive aripiprazole for schizophrenia with sexual dysfunction. Methods: 22 Japanese schizophrenia patients with antipsychotic-induced hyperprolactinemia and sexual dysfunction were enrolled, and 19 of them completed the study. Aripiprazole was administrated in a flexible titration schedule to participants according to the judgment of each doctor, and patients were followed for 24 weeks. Serum prolactin, Clinical Global Impression Scales-Severity (CGI-S), and Nagoya Sexual Function Questionnaire (NSFQ) were measured at baseline and at 4, 8, 12, and 24 weeks. Results: Prolactin at week 4 and later was significantly lower than that at baseline. Compared to baseline, we observed a significant improvement in total sexual dysfunction as measured by NSFQ at week 8 and later. In males, erectile dysfunction was significantly reduced at week 24. In females, menstrual irregularity and galactorrhea were significantly reduced at week 24. CGI-S did not significantly change. Discussion: Although the small sample size is a limitation in this study, adjunctive aripiprazole may be useful treatment for sexual dysfunction including hyperprolactinemia in schizophrenia.
- Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. [Journal Article]
- World J Biol Psychiatry 2016 Sep 22; :1-8WJ
- CONCLUSIONS: This study revealed an association between HPRL and X-chromosome haplotypes comprised of the rs569959 and rs17326429 polymorphisms.
- Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal. [Journal Article]
- Clin Endocrinol (Oxf) 2016 Sep 21CE
- CONCLUSIONS: Cabergoline therapy can achieve a high percentage (73% in this series) of remission maintenance for at least 12 months after cessation of a 5-year course of therapy, even in patients with macroprolactinomas. Absence of cavernous sinus invasion, serum PRL level lower than 132.7 ng/ml before cabergoline therapy, or nadir serum PRL below 1.9 ng/ml were related to more frequent remission after withdrawal of cabergoline in patients receiving this medication for 5 years. This article is protected by copyright. All rights reserved.
- [Andrologic consequences of chronic renal failure: State of the art for the yearly scientific report of the French National Association of Urology]. [Journal Article]
- Prog Urol 2016 Sep 16PU
- CONCLUSIONS: CKD is frequently associated with an hypogonadism whose correction is validated only in the setting of erectile dysfunction treatment. The other benefits of the correction of hypogonadism in the CKD patients, including overall survival, needs to be evaluated.
- [Hyperprolactinemia: unusual association between peripheral hypothyroidism and microprolactinoma]. [Journal Article]
- Pan Afr Med J 2016; 24:41PA
- We report a rare case of hyperprolactinemia revealing the association between peripheral hypothyroidism and prolactin pituitary macroadenomas. The patient was a 43-year old woman, presenting with spo...
We report a rare case of hyperprolactinemia revealing the association between peripheral hypothyroidism and prolactin pituitary macroadenomas. The patient was a 43-year old woman, presenting with spontaneous bilateral galactorrhea over a period of 1 year. Hyperprolactinemia was confirmed and etiologic investigation revealed peripheral hypothyroidism secondary to autoimmune thyroiditis. Therapy consisted of administration of thyroid hormone, with clinical stabilization and hormonal normalization three months later. The evolution was marked by the persistence of hyperprolactinemia and galactorrhea. The diagnosis of microprolactinoma was objectified by pituitary MRI which showed microadenoma, justifying the administration of antidopaminergic therapy Six months later, the evolution was marked by normalization of prolactin levels and disappearance of pituitary microadenoma image.
- Long-term outcome of macroprolactinomas. [Journal Article]
- Ann Endocrinol (Paris) 2016 Sep 15AE
- CONCLUSIONS: Macroprolactinoma is currently most often a chronic disease controlled with DA. However, uncertainty about the adverse effects associated with high cumulative doses and the lack of data on the prognosis at very long-term should incite to revisit current strategies, including the role of surgery combined to medical treatment.
New Search Next
- [Prolactin, antipsychotics and breast cancer: is there a connection?]. [Journal Article]
- Tijdschr Psychiatr 2016; 58(9):641-9TP
- CONCLUSIONS: There is no conclusive evidence that antipsychotic medication that raises prolactin levels increases the risk of breast cancer. Nevertheless, clinicians should always be cautious about prescribing antipsychotics for breast cancer patients. In our view, clinicians should always treat breast cancer risk factors as efficiently as possible, particularly when attending to patients who have schizophrenia.